[
    [
        {
            "time": "2018-11-26",
            "original_text": "Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Ex-Dividend",
                    "Scheduled"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-11-26",
            "original_text": "Novartis Gets Approval for Gene Therapy Luxturna in Europe",
            "features": {
                "keywords": [
                    "Novartis",
                    "Approval",
                    "Gene Therapy",
                    "Luxturna",
                    "Europe"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-26",
            "original_text": "Novartis's pricing might be tested with costly eye therapy",
            "features": {
                "keywords": [
                    "Novartis",
                    "pricing",
                    "tested",
                    "costly",
                    "eye therapy"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-11-26",
            "original_text": "U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million",
            "features": {
                "keywords": [
                    "U.S.",
                    "benefits",
                    "manager",
                    "baulks",
                    "Novartis",
                    "gene therapy",
                    "$4-5 million"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-11-26",
            "original_text": "Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval",
            "features": {
                "keywords": [
                    "Spark Therapeutics",
                    "One-time",
                    "Gene Therapy",
                    "LUXTURNA",
                    "EU",
                    "Approval"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-26",
            "original_text": "Novartis: EU Approves One-time Gene Therapy Luxturna To Restore Vision",
            "features": {
                "keywords": [
                    "Novartis",
                    "EU",
                    "Approves",
                    "One-time",
                    "Gene Therapy",
                    "Luxturna",
                    "Restore",
                    "Vision"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-26",
            "original_text": "Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "Cancer",
                    "Approvals",
                    "PFE",
                    "ABBV",
                    "CHMP",
                    "Nod",
                    "Drugs"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]